Effect of smoking behaviour and related blood DNA methylation on visceral adipose tissues.

IF 5.4 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Diabetes, Obesity & Metabolism Pub Date : 2024-11-07 DOI:10.1111/dom.16054
Zheng-Qi Song, Yi-Qi Chen, Chen-Hao Xuan, Tong-Tong Ni, Yu-Peng Xu, Xin-Yu Lu, Fang-Ran Chen, Yi-He Chen
{"title":"Effect of smoking behaviour and related blood DNA methylation on visceral adipose tissues.","authors":"Zheng-Qi Song, Yi-Qi Chen, Chen-Hao Xuan, Tong-Tong Ni, Yu-Peng Xu, Xin-Yu Lu, Fang-Ran Chen, Yi-He Chen","doi":"10.1111/dom.16054","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Recent studies have found that tobacco smoking is associated with fat distribution, yet limited research has focused on its relationship with visceral adipose tissues (VATs). Furthermore, the cellular and molecular mechanisms underlying the interactions among smoking, epigenetic modifications, and VATs remain unknown.</p><p><strong>Method: </strong>We performed univariable Mendelian randomization (MR) analysis to elucidate the causal relationship between smoking behaviours and VATs, including epicardial and pericardial adipose tissue (EPAT), liver fat (LF), and pancreas fat (PF). This approach could minimize the impact of confounders and reverse causality through utilizing genetic variants to proxy the smoking behaviours. Mediation MR analysis were conducted to detect potential mediators. Additionally, summary-data-based MR (SMR) and colocalization analysis were performed to explore the association between smoking-related DNA methylation and VATs.</p><p><strong>Results: </strong>We identified a convincing association between smoking initiation and increased EPAT (beta: 0.15, 95% CI: 0.06, 0.23, p = 7.01 × 10<sup>-4</sup>) and LF area (beta: 0.15, 95% CI = 0.05, 0.24, p = 2.85 × 10<sup>-3</sup>), respectively. Further mediation analysis suggested type 2 diabetes mellitus (T2DM) as a potential mediator within these co-relationships. When further exploring the associations between the smoking related DNA methylation and VATs, we identified that WT1 methylation at cg05222924 was significantly linked to a lower EPAT area (beta: -0.12, 95% CI: -0.16, -0.06, P<sub>FDR</sub> = 2.24 × 10<sup>-3</sup>), while GPX1 methylation at cg18642234 facilitated the deposition of EPAT (beta: 0.15, 95% CI: 0.10, 0.20, P<sub>FDR</sub> = 1.66 × 10<sup>-4</sup>).</p><p><strong>Conclusion: </strong>Our study uncovered a significant causal effect between smoking and VATs, with T2DM identified as a potential mediator. Further investigation into DNA methylation yielded novel insights into the pathogenic role of smoking on EPAT.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/dom.16054","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Recent studies have found that tobacco smoking is associated with fat distribution, yet limited research has focused on its relationship with visceral adipose tissues (VATs). Furthermore, the cellular and molecular mechanisms underlying the interactions among smoking, epigenetic modifications, and VATs remain unknown.

Method: We performed univariable Mendelian randomization (MR) analysis to elucidate the causal relationship between smoking behaviours and VATs, including epicardial and pericardial adipose tissue (EPAT), liver fat (LF), and pancreas fat (PF). This approach could minimize the impact of confounders and reverse causality through utilizing genetic variants to proxy the smoking behaviours. Mediation MR analysis were conducted to detect potential mediators. Additionally, summary-data-based MR (SMR) and colocalization analysis were performed to explore the association between smoking-related DNA methylation and VATs.

Results: We identified a convincing association between smoking initiation and increased EPAT (beta: 0.15, 95% CI: 0.06, 0.23, p = 7.01 × 10-4) and LF area (beta: 0.15, 95% CI = 0.05, 0.24, p = 2.85 × 10-3), respectively. Further mediation analysis suggested type 2 diabetes mellitus (T2DM) as a potential mediator within these co-relationships. When further exploring the associations between the smoking related DNA methylation and VATs, we identified that WT1 methylation at cg05222924 was significantly linked to a lower EPAT area (beta: -0.12, 95% CI: -0.16, -0.06, PFDR = 2.24 × 10-3), while GPX1 methylation at cg18642234 facilitated the deposition of EPAT (beta: 0.15, 95% CI: 0.10, 0.20, PFDR = 1.66 × 10-4).

Conclusion: Our study uncovered a significant causal effect between smoking and VATs, with T2DM identified as a potential mediator. Further investigation into DNA methylation yielded novel insights into the pathogenic role of smoking on EPAT.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
吸烟行为和相关血液 DNA 甲基化对内脏脂肪组织的影响。
背景:最近的研究发现,吸烟与脂肪分布有关,但有关吸烟与内脏脂肪组织(VATs)关系的研究却很有限。此外,吸烟、表观遗传修饰和内脏脂肪组织之间相互作用的细胞和分子机制仍然未知:我们进行了单变量孟德尔随机化(MR)分析,以阐明吸烟行为与心外膜和心包脂肪组织(EPAT)、肝脏脂肪(LF)和胰腺脂肪(PF)等VATs之间的因果关系。通过利用基因变异来替代吸烟行为,这种方法可以最大限度地减少混杂因素和反向因果关系的影响。为检测潜在的中介因素,进行了中介MR分析。此外,我们还进行了基于汇总数据的MR(SMR)和共定位分析,以探讨吸烟相关DNA甲基化与VATs之间的关联:结果:我们发现吸烟与 EPAT(β:0.15,95% CI:0.06,0.23,p = 7.01 × 10-4)和 LF 面积(β:0.15,95% CI = 0.05,0.24,p = 2.85 × 10-3)增加之间存在令人信服的关联。进一步的中介分析表明,2 型糖尿病(T2DM)是这些共同关系中的潜在中介。在进一步探讨与吸烟相关的 DNA 甲基化与 VATs 之间的关联时,我们发现 cg05222924 处的 WT1 甲基化与较低的 EPAT 面积显著相关(beta:-0.12,95% CI:-0.16,-0.06,PFDR = 2.24 × 10-3),而 cg18642234 处的 GPX1 甲基化促进了 EPAT 的沉积(beta:0.15,95% CI:0.10,0.20,PFDR = 1.66 × 10-4):我们的研究发现,吸烟与脂肪增值之间存在明显的因果关系,而 T2DM 被认为是潜在的中介因素。对DNA甲基化的进一步研究为了解吸烟对EPAT的致病作用提供了新的视角。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Diabetes, Obesity & Metabolism
Diabetes, Obesity & Metabolism 医学-内分泌学与代谢
CiteScore
10.90
自引率
6.90%
发文量
319
审稿时长
3-8 weeks
期刊介绍: Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.
期刊最新文献
One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA. The prognostic impact of the Stress Hyperglycemia Ratio on End-Stage Renal Disease among patients with Diabetic Kidney Disease. Effects of sotagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease stages 3 and 4. Glucagon-like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: A meta-analysis of randomised controlled trials. Incidence of diabetes mellitus following hospitalisation for COVID-19 in the United Kingdom: A prospective observational study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1